1. Angiogenic breast tumor by immunohistochemistry confirmation.

2. Positive scan with PET/CT imaging with 18F-FET PET/CT.

3. Tumor progression resistant or refractory to at least one prior lines of standard chemotherapy which include trastuzumab and/or Ado-trastuzumab with or without chemotherapy agents.

4. At least 18 years of age

5. The patient is able and willing to provide informed consent and to comply with the requirements of this trial protocol.

6. ECOG score ≤3

7. Females of childbearing potential must have a negative serum pregnancy test or have had an intervention that renders pregnancy not possible

8. Adequate organ function, defined as:

1. Absolute neutrophil count (ANC) ≥ 1.5 x 109/mL.

2. Hemoglobin (Hb) ≥10 g/dl (transfusion or use of EPO is permitted).

3. Platelets > 100,000/mm3

4. Creatinine ≤ 1.5 x upper limit of normal (ULN)

5. AST or ALT ≤ 2.5 x ULN (or ≤5 x ULN in case of liver metastasis)

6. Alkaline phosphatase ≤2.5 x ULN. Alkaline phosphatase may be more than 2.5 x ULN only in the case of bone metastases, and AST and ALT less than 1.5 x ULN.

7. Total bilirubin ≤1.5 mg/dl (higher bilirubin levels are permitted if the patient has Gilbert's syndrome).

9. Baseline LVEF ≥40% measured using echocardiogram or equilibrium isotopic ventriculography